An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Active autoimmune cytopenia
• Relapsed/refractory after ≥1 prior treatment
• Body weight ≥ 55 kg
• Willing to comply with and study requirements and procedures
Locations
Other Locations
Australia
Icon Cancer Center South Brisbane
RECRUITING
Brisbane
The Canberra Hospital
RECRUITING
Canberra
Liverpool Hospital
RECRUITING
Sydney
Contact Information
Primary
Study Sponsor
info@ouromeds.com
415-429-4887
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2027-09
Participants
Target number of participants: 32
Treatments
Experimental: OM336 Dose Escalation
Participants will receive OM336 via subcutaneous injection in ascending dose cohorts
Related Therapeutic Areas
Sponsors
Leads: Ouro Medicines